1417334-68-9

Basic information

• Product Name: C₂₅H₁₉N₃O₄S
• Synonyms: C₂₅H₁₉N₃O₄S
• CAS NO: 1417334-68-9
• Molecular Weight: 457.51
• Mol File: 1417334-68-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₅H₁₉N₃O₄S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₅H₁₉N₃O₄S(1417334-68-9)
• EPA Substance Registry System: C₂₅H₁₉N₃O₄S(1417334-68-9)

Safety Data

• Hazardous Substances Data: 1417334-68-9(Hazardous Substances Data)

Upstream product

• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 20197-75-5 2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid methyl ester 
• 5720-05-8 4-methylphenylboronic acid 
• 138642-47-4 2-bromo-5-methoxybenzonitrile 
• 928710-56-9 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1,3,4-oxadiazole-2-thiol 
• 1428147-20-9 C₁₅H₁₂BrNO 
• 98953-13-0 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylic acid hydrazide 

Relevant articles and documents

Structure-based optimization of oxadiazole-based GSK-3 inhibitors

Inhibition of glycogen synthase kinase-3 (GSK-3) induces neuroprotective effects, e.g. decreases β-amyloid production and reduces tau hyperphosphorylation, which are both associated with Alzheimer's disease (AD). The two isoforms of GSK-3 in mammalians are GSK-3α and β, which share 98% homology in their catalytic domains. We investigated GSK-3 inhibitors based on 2 different scaffolds in order to elucidate the demands of the ATP-binding pocket [1]. Particularly, the oxadiazole scaffold provided potent and selective GSK-3 inhibitors. For example, the most potent inhibitor of the present series, the acetamide 26d, is characterized by an IC50 of 2 nM for GSK-3α and 17 nM for GSK-3β. In addition, the benzodioxane 8g showed up to 27-fold selectivity for GSK-3α over GSK-3β, with an IC 50 of 35 nM for GSK-3α. Two GSK-3 inhibitors were further profiled for efficacy and toxicity in the wild-type (wt) zebrafish embryo assay to evaluate simultaneously permeability and safety.